Monica Bertagnolli
#45,586
Most Influential Person Now
American surgical oncologist | Director, National Cancer Institute
Monica Bertagnolli's AcademicInfluence.com Rankings
Monica Bertagnollimedical Degrees
Medical
#456
World Rank
#626
Historical Rank
Oncology
#105
World Rank
#109
Historical Rank
Download Badge
Medical
Why Is Monica Bertagnolli Influential?
(Suggest an Edit or Addition)According to Wikipedia, Monica Bertagnolli is an American surgical oncologist and the 17th director of the National Institutes of Health. She previously served as the 16th director of the National Cancer Institute. Prior to her governmental positions, she worked at Brigham and Women's Hospital and Dana–Farber Cancer Institute and was the Richard E. Wilson Professor of Surgery at Harvard Medical School. She has advocated for inclusion of rural communities in clinical studies and served as Chair of the Alliance for Clinical Trials in Oncology until her appointment to lead NCI. Bertagnolli specializes in the treatment of tumors from gastrointestinal diseases and soft tissue sarcomas. She is the former President of the American Society of Clinical Oncology and was elected Fellow of the National Academy of Medicine in 2021. In 2023, President Biden nominated Bertagnolli to serve as the director of the National Institutes of Health. Dr. Bertagnolli was confirmed by the United States Senate on November 7, 2023. She is the second woman director of the NIH.
Monica Bertagnolli's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Comprehensive molecular characterization of human colon and rectal cancer (2012) (6141)
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq (2016) (2825)
- Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention (2005) (2002)
- Molecular origins of cancer: Molecular basis of colorectal cancer. (2009) (1631)
- Celecoxib for the prevention of sporadic colorectal adenomas. (2006) (1030)
- Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. (1996) (615)
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial (2017) (580)
- Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. (2008) (559)
- Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. (2006) (436)
- CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). (2014) (430)
- Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. (2009) (376)
- Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis (2008) (349)
- Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. (2000) (343)
- Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia (2002) (339)
- Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). (2016) (311)
- The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. (2007) (295)
- Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. (2004) (292)
- Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas (2006) (290)
- Characterization of sporadic colon cancer by patterns of genomic instability. (2003) (284)
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 (2011) (258)
- Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. (2002) (234)
- Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. (2013) (232)
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (213)
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 (2009) (194)
- Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial (2009) (190)
- Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. (2019) (182)
- BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. (2009) (172)
- Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. (1997) (171)
- Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. (2011) (167)
- Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery (2010) (167)
- IL-12 augments antigen-dependent proliferation of activated T lymphocytes. (1992) (160)
- Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. (2013) (155)
- The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. (1998) (151)
- Sentinel Node Staging of Resectable Colon Cancer: Results of a Multicenter Study (2004) (140)
- Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). (2019) (137)
- Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. (2000) (127)
- Aspirin prevents tumors in a murine model of familial adenomatous polyposis. (1998) (127)
- Celecoxib pathways: pharmacokinetics and pharmacodynamics. (2012) (122)
- Predictors for Major Wound Complications Following Preoperative Radiotherapy and Surgery for Soft-Tissue Sarcoma of the Extremities and Trunk: Importance of Tumor Proximity to Skin Surface (2013) (115)
- 501OCALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH EXPANDED RAS ANALYSES UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM (MCRC) (2014) (114)
- Apc Deficiency Is Associated with Increased Egfr Activity in the Intestinal Enterocytes and Adenomas of C57BL/6J-Min/+ Mice* (2004) (113)
- Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). (2016) (113)
- Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers (2004) (112)
- (+)-Catechin inhibits intestinal tumor formation and suppresses focal adhesion kinase activation in the min/+ mouse. (2001) (111)
- CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. (2014) (107)
- Reciprocal Expression of ERα and ERβ Is Associated with Estrogen-mediated Modulation of Intestinal Tumorigenesis (2001) (105)
- 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors (2009) (104)
- Leiomyosarcoma of the Inferior Vena Cava: Survival After Aggressive Management (2007) (102)
- TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres (2011) (99)
- Secondary sarcomas after radiotherapy for breast cancer (2009) (95)
- Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. (2014) (92)
- APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q1 (2004) (92)
- Desmoid-Type Fibromatosis and Pregnancy: A Multi-institutional Analysis of Recurrence and Obstetric Risk (2014) (89)
- Estrogen Receptors α and β Are Inhibitory Modifiers of Apc-Dependent Tumorigenesis in the Proximal Colon of Min/+ Mice (2006) (87)
- Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. (1999) (87)
- Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse. (2005) (86)
- Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance) (2013) (84)
- Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. (2000) (84)
- Comparison of Gastric Cancer Survival Between Caucasian and Asian Patients Treated in the United States: Results from the Surveillance Epidemiology and End Results (SEER) Database (2015) (84)
- Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. (2004) (81)
- Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. (2007) (80)
- Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. (2010) (78)
- Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. (2011) (77)
- Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac. (1999) (77)
- Multimodality treatment of mesenteric desmoid tumours. (2008) (74)
- Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. (2014) (73)
- Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. (2001) (73)
- Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate (2010) (73)
- Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). (2017) (73)
- Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. (2011) (72)
- Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2020) (69)
- Advantages of a Truly Open-Access Data-Sharing Model. (2017) (69)
- Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. (2006) (68)
- Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. (2019) (67)
- Association of family history with cancer recurrence and survival among patients with stage III colon cancer. (2008) (67)
- Accuracy of EUS and CT imaging in preoperative gastric cancer staging (2015) (65)
- 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. (2002) (62)
- Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. (2012) (58)
- Surgical Management of Primary Retroperitoneal Sarcomas: Rationale for Selective Organ Resection (2017) (58)
- Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial (2008) (56)
- Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT (2005) (56)
- Locoregional Recurrence After Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Adverse Impact of Multifocal Disease and Potential Implications of Dose Escalation (2013) (56)
- Celecoxib inhibits early cutaneous wound healing. (2015) (55)
- Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). (2017) (54)
- Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. (2007) (54)
- Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis (2017) (53)
- IL-7 supports the generation of cytotoxic T lymphocytes from thymocytes. Multiple lymphokines required for proliferation and cytotoxicity. (1990) (53)
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (53)
- Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. (2009) (52)
- Progressive Changes in Adherens Junction Structure during Intestinal Adenoma Formation in Apc Mutant Mice* (2001) (52)
- Combined sentinel lymphadenectomy and mohs micrographic surgery for high-risk cutaneous squamous cell carcinoma. (2000) (51)
- Evaluation of Microsatellite Instability, hMLH1 Expression and hMLH1 Promoter Hypermethylation in Defining the MSI Phenotype of Colorectal Cancer (2004) (49)
- Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. (2013) (48)
- KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. (2015) (47)
- Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. (2009) (47)
- Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. (2004) (47)
- Choledochal cysts in adults: a report of two cases and review of the literature. (1998) (47)
- Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. (2009) (46)
- Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) (2020) (45)
- Accelerating anticancer drug development — opportunities and trade-offs (2018) (44)
- Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. (2013) (44)
- Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). (2016) (43)
- Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance) (2017) (41)
- Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803 (2013) (40)
- Evidence that rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes. (1994) (39)
- Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. (2010) (39)
- Immunomodulatory Effects of Interleukin‐12 on Human Tumor‐Infiltrating Lymphocytes (1993) (39)
- Cutaneous Radiation-associated Breast Angiosarcoma: Radicality of Surgery Impacts Survival (2017) (36)
- Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways (2018) (35)
- Amputation for Extremity Sarcoma: Contemporary Indications and Outcomes (2018) (35)
- Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial (2010) (35)
- Incidence and Adverse Prognostic Implications of Histopathologic Organ Invasion in Primary Retroperitoneal Sarcoma. (2017) (32)
- Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. (2021) (31)
- p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803 (2009) (30)
- Systematic meta-analyses and field synopsis of genetic association studies in colorectal adenomas. (2016) (30)
- Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. (2006) (29)
- Chronic Cyclooxygenase-2 Inhibition Promotes Myofibroblast-Associated Intestinal Fibrosis (2010) (27)
- Estrogen receptor α or β loss in the colon of Min/+ mice promotes crypt expansion and impairs TGFβ and HNF3β signaling. (2014) (26)
- C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment (2011) (26)
- O-0019CALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH KRAS WILD-TYPE (WT) UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON (2014) (25)
- Bidirectional cross talk between patient‐derived melanoma and cancer‐associated fibroblasts promotes invasion and proliferation (2016) (25)
- Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. (2006) (25)
- Evaluation of the contralateral breast. The role of biopsy at the time of treatment of primary breast cancer. (1992) (24)
- A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions (2008) (24)
- Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance). (2017) (23)
- Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. (2011) (23)
- Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs) (2007) (22)
- Insulin Resistance in Vascular Endothelial Cells Promotes Intestinal Tumor Formation (2017) (22)
- Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1 (2020) (22)
- Ethical aspects of participation in the Database of Genotypes and Phenotypes of the National Center for Biotechnology Information (2012) (22)
- Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH (2018) (22)
- LBA10CALGB/SWOG 80405: ANALYSIS OF PATIENTS UNDERGOING SURGERY AS PART OF TREATMENT STRATEGY (2014) (22)
- Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. (2006) (18)
- Society of University Surgeons statement on surgical resident work hours and education. (2002) (18)
- MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial (2014) (18)
- A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803 (2016) (17)
- Laparoscopic colon resection for cancer--an unfavorable view. (1996) (17)
- Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance). (2021) (17)
- Antitumor effects of hyaluronan inhibition in desmoid tumors. (2015) (17)
- Adenomatous polyposis coli truncation alters cytoskeletal structure and microtubule stability in early intestinal tumorigenesis (2002) (16)
- Predictive Biomarkers and Personalized Medicine Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer : Results from CALGB 80303 ( Alliance ) (2013) (16)
- The electronic health record as a clinical trials tool: Opportunities and challenges (2020) (16)
- The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma (2011) (15)
- The potential of non‐steroidal anti‐inflammatory drugs (NSAIDs) for colorectal cancer prevention (2003) (15)
- Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. (2011) (15)
- Fibromatosis of the Breast: Diagnostic Accuracy of Core Needle Biopsy (2017) (15)
- Treatment of Older Adults with Cancer - Addressing Gaps in Evidence. (2021) (15)
- Laparoscopic colectomy for cancer (1995) (14)
- Safety and Efficacy of Radiation Dose Delivered via Iodine-125 Brachytherapy Mesh Implantation for Deep Cavity Sarcomas (2015) (14)
- Surgical prevention of cancer. (2005) (14)
- Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors (2007) (14)
- The forest and the trees: pathways and proteins as colorectal cancer biomarkers. (2009) (13)
- Colon Cancer Prevention: Intervening in a Multistage Process (1997) (13)
- Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study (2013) (12)
- Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors. (2012) (12)
- Enhanced recovery after surgery pathway in patients with soft tissue sarcoma (2020) (12)
- Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. (2009) (11)
- Cyclooxygenase-2 as a target for prevention of colorectal cancer (1999) (11)
- Radioimmunotherapy for Colorectal Cancer (2005) (11)
- APC and Intestinal Carcinogenesis Insights from Animal Models (1999) (11)
- IL-4-supported induction of cytolytic T lymphocytes requires IL-2 and IL-6. (1991) (10)
- Status Update on Data Required to Build a Learning Health System. (2020) (10)
- KIT hyperactivation in imatinib-resistant GIST: Implications for salvage therapies (2005) (9)
- Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy (2018) (7)
- Cox-2 and cancer chemoprevention: picking up the pieces. (2007) (7)
- KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. (2016) (7)
- What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report (2020) (7)
- Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581. (2014) (7)
- Expanding public-private collaborations to enhance cancer drug development: a report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century". (2014) (6)
- PROFILE: Broadly based genomic testing for all patients at a major cancer center. (2013) (6)
- Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition (2022) (6)
- Debulking of a gastrointestinal hemangioma alleviates coagulopathy associated with Kasabach-Merritt syndrome. (1999) (5)
- Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): Novel mutated genes and their effect on response to therapy (Alliance) (2019) (5)
- Surgical aspects of colorectal carcinoma. (1997) (5)
- Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens (2021) (5)
- Cytokines and t Lymphocytes: Therapeutic Manipulation of the Immune System (1993) (5)
- Current Activities of the Coalition of Cancer Cooperative Groups. (2018) (4)
- Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (4)
- Staged antrectomy and thoracoscopic truncal vagotomy for perforated peptic ulcer disease. (1993) (4)
- Abstract LB-141: The Adenoma Prevention with Celecoxib (APC) trial: Five-year efficacy and safety results (2008) (4)
- Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance). (2017) (4)
- Colorectal Cancer Prevention Studies: The Importance of Defining Disease Risk (2003) (4)
- Controversies in the surgical management of GIST in the era of imatinib. (2009) (4)
- Sentinel node staging of resectable colon cancer: Results of CALGB 80001. (2004) (4)
- The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. (2012) (4)
- Aspirin and colon cancer prevention. (1998) (4)
- Celecoxib for prevention of sporadic colorectal adenomas: Patient selection to optimize efficacy and safety (2008) (3)
- Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE). (2018) (3)
- Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). (2006) (3)
- Approaches to immunotherapy of cancer: characterization of lymphokines as second signals for cytotoxic T-cell generation. (1991) (3)
- p 27 Kip 1 in Stage IIIColon Cancer : Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group BProtocol 89803 (2009) (3)
- Prostaglandin Inhibition and Cardiovascular Risk: Maybe Timing Really Is Everything (2009) (3)
- The 2010 Institute of Medicine consensus statement "A national clinical trials network for the 21st century": progress and challenges. (2014) (3)
- The authors reply [9] (2006) (3)
- Doing our best: surgery for rectal cancer (2008) (3)
- Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance) (2020) (3)
- Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405. (2015) (2)
- Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients (2020) (2)
- Choledochal cysts in adults (1998) (2)
- Cyclooxygenase-2 and Chronic Inflammation: Drivers of Colorectal Tumorigenesis (2012) (2)
- 7522 POSTER Postoperative experience in patients with metastatic GIST are similar in patients while on sunitinib or imatinib (2007) (2)
- Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST (2022) (2)
- Abstract LB-173: Statin use and colorectal adenoma risk: Results from the Adenoma Prevention with Celecoxib (APC) trial (2010) (2)
- Retroperitoneal Sarcoma (RPS): Evaluation of Locoregional Recurrences (LRR) After Preoperative Radiation Therapy (RT) and Potential Benefit of Dose Escalation Using Dose Painting (2012) (2)
- Composite grading algorithm for National Cancer Institute’s PRO-CTCAE. (2020) (2)
- T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development (2016) (2)
- (+)-Catechin inhibits tumor formation and modulates integrin-mediated signaling in vitro and in vivo. (2000) (2)
- Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702. (2020) (2)
- Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8). (2018) (2)
- ( 1 )-Catechin Inhibits Intestinal Tumor Formation and Suppresses Focal Adhesion Kinase Activation in the Min/ 1 Mouse 1 (2000) (2)
- Gastrointestinal Stromal Tumors of Gastric Origin (2009) (2)
- Tumor immunogenomic features determine outcomes in metastatic colorectal cancer patients treated with standard-of-care combinations of bevacizumab and cetuximab. (2022) (1)
- Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary results (2005) (1)
- Predictive role of aberrant crypt foci (ACF) as surrogate endpoint biomarkers of colorectal cancer. (2006) (1)
- Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC). (2021) (1)
- Expression of COX-2 and 15-PGDH in adenomas removed during pretreatment colonoscopy to predict chemopreventive efficacy of the selective COX-2 inhibitor, celecoxib. (2017) (1)
- Value assessment frameworks in oncology: championing concordance through shared standards. (2019) (1)
- Abstract 3794: Sorafenib suppresses desmoid tumor growth and invasion via inhibition of ERK signaling (2014) (1)
- Abstract 15111: Genome-Wide Association Study Links Variants With Occurrence of Cardiovascular Events in People Taking the COX-2 Inhibitor Celecoxib: Identification of NCKX2 as a Novel Protective Pathway in Renal Vessels (2017) (1)
- Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment (2008) (1)
- Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes (2023) (1)
- Value assessment frameworks in oncology: championing concordance through shared standards. (2019) (1)
- A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803. (2012) (1)
- 2019 ASCO Presidential Address: Caring for Every Patient, Learning From Every Patient. (2019) (1)
- Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance). (2020) (1)
- W1104 The Influence of Genetic Variation in the Cytochrome P450 2c9 Enzyme in a Randomized Trial of Celecoxib for the Prevention of Sporadic Colorectal Adenoma (2008) (1)
- Lack of anti-tumor activity with the β-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of intestinal carcinogenesis. (2014) (1)
- Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the phenotype of colorectal cancer: a study from CALGB 9865 (2003) (1)
- Cancer and Leukemia Group B Gastrointestinal Cancer Committee (2006) (1)
- A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405. (2015) (1)
- Molecular characterization and management of secondary resistance to serial TRK inhibitors. (2019) (1)
- Cancer Care in the Rural United States: A Visitor's Perspective From Appalachian Ohio; Pine Ridge, South Dakota; and Sidney, Montana. (2020) (0)
- Phytoestrogen-mediated suppression of Apc-associated intestinal tumorigenesis (2003) (0)
- Sorafenib Suppresses Translation in Desmoid Tumors via Inhibition of mTOR Signaling (2014) (0)
- Reply to L. Casadaban et al. (2017) (0)
- In Memoriam: Jimmie C. Holland, M.D., and James F. Holland, M.D. (2018) (0)
- Desmoid fibromatosis and pregnancy: A multi-institutional analysis of recurrence and obstetric risk. (2012) (0)
- Adjudication of GI Events from Long-Term Placebo-Controlled Trials Provides Evidence for GI Safety and Tolerability of Celecoxib vs Placebo: 147 (2007) (0)
- 7503 ORAL KIT mutations and sunitinib resistance in gastrointestinal stromal tumors (GISTs) (2007) (0)
- Linking genotype to phenotype: bench to bedside. (2022) (0)
- A novel, open-access data commons for improved disease management in patients (pts) with Merkel cell carcinoma (MCC). (2018) (0)
- Sorafenib Suppresses Desmoid Tumor Growth and Invasion via Inhibition of ERK Signaling (2014) (0)
- Cutaneous Radiation-associated Breast Angiosarcoma ry Impacts Survival Radicality of Surge (2016) (0)
- Microsatellite-high (MSI-H) tumors are not associated with LOH at the APC locus compared to microsatellite-low/stable (MSI-L/MSS) tumors (2001) (0)
- Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405. (2022) (0)
- Abstract A31: Intestinal resistance to celecoxib in Min/+ mice involves ECM changes and an expanded population of TGFβ-expressing myofibroblasts (2008) (0)
- A panel of mono- and dinucleotide microsatellite markers is required for reliable determination of the MSI status in colorectal cancer (2001) (0)
- Interpreting the Inconsistent Data Concerning the Role of 18qLOH as a Prognostic Marker for Colorectal Cancer (2010) (0)
- Abstract 3304: Hyaluronan mediates interactions between CD44+ MSCs and CD34+ fibrocytes in Desmoid Tumors. (2012) (0)
- Abstract LB-242: Aberrant crypt foci (ACF) are not surrogate biomarkers of sporadic adenoma prevention with celecoxib: Results from the Adenoma Prevention with Celecoxib (APC) trial (2008) (0)
- Current management of metastatic gastrointestinal stromal tumor: a case report. (2003) (0)
- Robert L. Comis: In Memoriam (2017) (0)
- Edinburgh Research Explorer Germline Variants and Advanced Colorectal Adenomas (2017) (0)
- p27 Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 (2011) (0)
- Mo1799 Limitations of EUS and CT for Preoperative Staging of Gastric Cancer (2014) (0)
- Abstract 2863: Long term COX-2 inhibition in the small intestine of C57BL/6JApc+/+mice altered TGFβ signaling (2010) (0)
- Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study. (2021) (0)
- Abstract 2292: Absent E2 liganded AhR inhibits tumor inhibition by ERα in Min mice (2011) (0)
- Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (0)
- ASPIRIN AND COLON CANCER PREVENTION. AUTHORS' REPLY (1998) (0)
- Abstract 4514: A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803 (2012) (0)
- Implementation of single-cell genomics as a translational tool in patients with metastatic melanoma. (2016) (0)
- Treatment and Prevention of Intraepithelial Neoplasia : An Important Target for Accelerated New Agent Development Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia 1 (2002) (0)
- OP-IJEJ150184 1..20 (2015) (0)
- Dietary celecoxib treatment normalized excessive wound healing responses in Min/+ relative to Apc+/+ (WT) mice (2011) (0)
- Rejoinder (2020) (0)
- W1962 Genetic Variation in the Ugt1a6 Enzyme, Aspirin Use, and Adenoma “Rebound” Associated with Withdrawal of Celecoxib Treatment (2009) (0)
- Reply to S. Sorscher. (2019) (0)
- VICTOR spoiled? (2010) (0)
- 1503O Clinical and scientific impact of National Cancer Institute: Sponsored clinical trial network group treatment trials (2021) (0)
- Abstract 484: Persistent activation of mesenchymal stromal cells (MSCs) and tissue repair in the etiology of desmoid tumors (DT) (2011) (0)
- OP-JNCI180220 11..18 (2019) (0)
- Achieving the Goals of the Cancer Moonshot Requires Progress against All Cancers. (2023) (0)
- Abstract 1521: Expression of the tight junctions protein IGSF5 in the colorectal adenoma-carcinoma sequence (2012) (0)
- Genetic variation in the cytochrome P450 2C9 enzyme and dose of Celecoxib in the prevention of colorectal adenoma (2008) (0)
- Cox-2-cancer chemoprevention: Picking up the pieces (2006) (0)
- Descriptive Analysis of SARS-CoV-2 Genomics Data from Ambulatory Patients (2023) (0)
- Runx3: A novel tumor suppressor gene frequently inactivated by promoter hypermethylation in colon cancers-results from CALGB 9865 study (2003) (0)
- Somatic frameshift mutations in MBD4 (MED1) are not exclusively associated with microsatellite high (MSI-H) colorectal tumors (2001) (0)
- Abstract 1429:Apcheterozygosity in the C57BL/6J-Min/+ mouse produces an abnormal exuberant proliferative response in excisional wound healing (2011) (0)
- M1177 Risk of Colorectal Adenoma Recurrence Due to Red Blood Cell Folate Level in the Post Folate Fortification Era: Results From the Adenoma Prevention With Celecoxib (APC) Trial (2010) (0)
- Trauma/Critical Care 5: Basic Science - Wound HealingCelecoxib Inhibits Wound Healing Response in C57L/6J WT Mice (2014) (0)
- 2018 John H. Gibbon Jr. Lecture: Cancer Clinical Trials - A Surgeon's Perspective (2018) (0)
- Chromosomal vs microsatellite instability in colorectal cancers: Evidence for previously unrecognized pathways (2001) (0)
- 2007 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 (2015) (0)
- Comment re: “Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention” and “Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial” (2008) (0)
- W1913 A Prospective Study of C-Reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment (2009) (0)
- Abstract A013: CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance (2022) (0)
- Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients (2021) (0)
- Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance) (2022) (0)
- B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development (2015) (0)
- Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance). (2021) (0)
This paper list is powered by the following services:
Other Resources About Monica Bertagnolli
What Schools Are Affiliated With Monica Bertagnolli?
Monica Bertagnolli is affiliated with the following schools:
